In this Expert Perspective, Richard Kay, senior research associate at the Wellcome Trust MRC Institute of Metabolic Science at Cambridge University, discusses how mass spectrometry and triple quadrupole systems are being used to study the peptidome of people with diabetes and post-bariatric surgery. Richard also provides his thoughts on the benefits and challenges of using mass spectrometry compared with immunoassays for peptide analysis and how he envisages this research will evolve over the next 5-10 years.
About the author:
Richard Kay has 15 years experience at a contract research organisation developing LC-MS methods for quantifying peptides and proteins from pre-clinical and clinical trials supporting biopharmaceutical drug development. He has had extensive use of triple quadrupole instruments and high resolution mass spectrometers and has been involved in the development of extraction methods for purifying peptides and proteins from plasma and serum matrices for mass spectrometric analysis. Richard moved to Cambridge University to set up the peptidomics facility in the Annexe, running a nano flow and high flow rate system linked to a Q-Exactive plus for peptide analysis. The aim of the service is to support the MRL and other groups within Cambridge and further afield with peptidomics studies.
Video exclusively published on Video Journal of Biomedicine.